Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Ferring Pharmaceuticals Announces Major Restructuring, Cutting 500 Jobs Globally

Ferring Pharmaceuticals Announces Major Restructuring, Cutting 500 Jobs Globally

Ferring Pharmaceuticals, a privately owned Swiss company, has unveiled plans for a significant reorganization that will result in the reduction of its global workforce by approximately 7%. The restructuring effort, aimed at streamlining operations and enhancing strategic flexibility, will impact around 500 employees across the company's international locations.

NoahAI News10/9/2025
Highmark Health Names Karen Hanlon as President, Strengthening Leadership Team

Highmark Health Names Karen Hanlon as President, Strengthening Leadership Team

In a significant leadership change, Pittsburgh-based Highmark Health has appointed Karen Hanlon as its new president, effective immediately. This strategic move comes as the healthcare giant continues to navigate industry challenges and focus on delivering improved health experiences for its customers.

NoahAI News10/9/2025
Zenas BioSciences Inks $2B+ Deal with InnoCare, Betting Big on Autoimmune Therapies

Zenas BioSciences Inks $2B+ Deal with InnoCare, Betting Big on Autoimmune Therapies

In a significant move that underscores the growing trend of international pharmaceutical collaborations, Boston-based Zenas BioSciences has entered into a global licensing agreement with Beijing's InnoCare Pharma. The deal, potentially worth over $2 billion, centers on multiple autoimmune drug candidates and highlights the industry's continued interest in Chinese innovation.

NoahAI News10/8/2025
Boehringer Ingelheim's Jascayd Breaks Decade-Long Drought in Idiopathic Pulmonary Fibrosis Treatment

Boehringer Ingelheim's Jascayd Breaks Decade-Long Drought in Idiopathic Pulmonary Fibrosis Treatment

The U.S. Food and Drug Administration (FDA) has approved Boehringer Ingelheim's twice-daily pill nerandomilast, branded as Jascayd, for the treatment of idiopathic pulmonary fibrosis (IPF). This approval marks the first new treatment for IPF, a rare respiratory condition, in more than a decade.

NoahAI News10/8/2025
HHS Awards $48M for Kernal's mRNA CAR T Program Despite Recent Vaccine Pullback

HHS Awards $48M for Kernal's mRNA CAR T Program Despite Recent Vaccine Pullback

The Department of Health and Human Services (HHS) has granted a substantial $48 million award to Kernal Bio for its innovative mRNA-based CAR T-cell program, focusing on multiple sclerosis and B-cell malignancies. This funding, administered through the Advanced Research Projects Agency for Health (ARPA-H), comes just two months after the department's controversial decision to terminate approximately $500 million in funding for mRNA vaccine research.

NoahAI News10/8/2025
Government Shutdown Impacts FDA, Industry Gathers for Cell and Gene Therapy Meeting

Government Shutdown Impacts FDA, Industry Gathers for Cell and Gene Therapy Meeting

The U.S. pharmaceutical industry faces significant challenges and developments as the government shutdown enters its second week, halting new drug reviews at the FDA. Meanwhile, cell and gene therapy leaders convene in Phoenix for their annual meeting, and major pharmaceutical companies respond to looming tariffs with new pricing agreements.

NoahAI News10/8/2025
Medtech M&A Activity Poised for Resurgence as Industry Giants Signal Readiness

Medtech M&A Activity Poised for Resurgence as Industry Giants Signal Readiness

In a year marked by slower-than-usual dealmaking, executives from medical technology powerhouses Stryker and Johnson & Johnson have signaled a renewed appetite for acquisitions, potentially heralding a resurgence in industry M&A activity. Despite macroeconomic headwinds, including higher interest rates and unpredictable tariff policies, these industry leaders view strategic acquisitions as crucial to their growth strategies and are actively seeking opportunities to expand their portfolios.

NoahAI News10/8/2025
Nilo Therapeutics Launches with $101M to Harness Neural Circuits for Immune Disorders

Nilo Therapeutics Launches with $101M to Harness Neural Circuits for Immune Disorders

Nilo Therapeutics, a New York-based biotech startup, has emerged from stealth mode with a substantial $101 million Series A funding round. The company aims to develop novel treatments for autoimmune and inflammatory diseases by leveraging the body-brain axis and neural circuits.

NoahAI News10/8/2025
Takeda's Strategic Shift: Abandoning Cell Therapy Ambitions

Takeda's Strategic Shift: Abandoning Cell Therapy Ambitions

Takeda Pharmaceutical Company, the Japanese pharmaceutical giant, has announced a significant shift in its research and development strategy, discontinuing its cell therapy programs and refocusing efforts on small molecules, biologics, and antibody-drug conjugates. This decision marks a dramatic reversal of the company's recent investment strategy and has sent ripples through the pharmaceutical industry.

NoahAI News10/8/2025
Sanofi's Radioligand Therapy Shows Promise in Phase 2 Neuroendocrine Tumor Trial

Sanofi's Radioligand Therapy Shows Promise in Phase 2 Neuroendocrine Tumor Trial

Sanofi's recent foray into the radioligand therapy space appears to be yielding positive results, as their novel treatment for neuroendocrine tumors hits key endpoints in a phase 2 clinical trial. The pharmaceutical giant's €100 million ($110 million) investment in AlphaMedix, a targeted alpha therapy, is showing signs of clinical efficacy and a manageable safety profile in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

NoahAI News10/8/2025
AI-Powered Prostate Cancer Diagnostics: Alpenglow and Virdx Join Forces

AI-Powered Prostate Cancer Diagnostics: Alpenglow and Virdx Join Forces

In a significant development for prostate cancer diagnostics, Alpenglow Biosciences and Virdx have announced a multiyear strategic partnership aimed at creating next-generation AI-powered tools for improved cancer detection. The collaboration, which leverages Nvidia's advanced computing technology, promises to bridge the gap between radiology and pathology in prostate cancer diagnosis.

NoahAI News10/8/2025
Former FDA Officials Join Eli Lilly, Sparking Revolving Door Debate

Former FDA Officials Join Eli Lilly, Sparking Revolving Door Debate

Eli Lilly has announced the appointment of Peter Marks, M.D., Ph.D., as senior vice president of molecule discovery and head of infectious disease. Marks, the former director of the FDA's Center for Biologics Evaluation and Research (CBER), joins the pharmaceutical giant six months after his controversial departure from the regulatory agency.

NoahAI News10/8/2025
«1...484950...67»